To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
Clinical trial NCT06742138 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06742138
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-01-01
- Primary completion
- 2027-12-01
- Enrollment
- 284
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.